Tesofensine
NS2330
An orally active small-molecule triple monoamine reuptake inhibitor (serotonin, noradrenaline, and dopamine), originally developed for neurodegenerative disease and later studied in obesity and metabolic trials. It is a small molecule, not a peptide.
Half-life
~9 days (~220 h), oral. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Orally administered small molecule; store cool and dry, away from moisture, heat, and light.
References
- Astrup et al., Lancet 2008 (TIPO-1 phase 2)
- PubMed: tesofensine pharmacokinetics
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.